Company Performance - Prothena reported a quarterly loss of $1.86 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.11, and a significant decline from earnings of $1.22 per share a year ago, indicating an earnings surprise of -67.57% [1] - The company posted revenues of $4.42 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 79.2%, and a stark decrease from year-ago revenues of $132.01 million [2] - Over the last four quarters, Prothena has only surpassed consensus EPS estimates once and has not beaten consensus revenue estimates during the same period [2] Stock Performance - Prothena shares have declined approximately 50.8% since the beginning of the year, contrasting with the S&P 500's gain of 6.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.96 on revenues of $24.8 million, and for the current fiscal year, it is -$3.94 on revenues of $39.34 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Prothena belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting that the industry outlook could negatively impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could be a useful metric for investors [5]
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates